相关临床试验
29
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
14
48.3%
尚未招募
10
34.5%
招募中
5
17.2%
暂无批准数据
- Korean researchers used an oxygen-to-nitrogen atom swap to convert the furan group in natural products into pyrroles, dramatically altering biological activity. - The 15N-labeled limonin analog 15N-LIMO bound metabolic and mitochondrial proteins such as NNT instead of the kinases targeted by parent limonin. - Both limonin and 15N-LIMO showed antifibrotic activity through different mechanisms, with 15N-LIMO acting on mitochondrial redox systems and proving less cytotoxic. - A separate Ritsumeikan team reported a chlorine-guided, room-temperature method that deletes a carbonyl group from hydroxycoumarins to form coumaranones in over 99% yield.
- Researchers discovered that phosphodiesterase 3 (PDE3) inhibitors, currently used for heart disease and thrombosis, can stimulate bone growth by enhancing calcium influx into bone cells. - The study demonstrated that cilostazol treatment significantly increased bone outgrowth in cultured bones and body length in young mice over four weeks. - PDE3 inhibitors work by elevating cGMP levels in chondrocytes, amplifying the CNP signaling pathway that drives extracellular matrix synthesis and bone growth. - The findings suggest potential repurposing of existing PDE3 inhibitors for treating skeletal growth disorders like achondroplasia and idiopathic short stature.
